Comparative Pharmacology
Head-to-head clinical analysis: LIQUAEMIN SODIUM versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUAEMIN SODIUM versus PRADAXA.
LIQUAEMIN SODIUM vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating the inactivation of thrombin and factor Xa, thereby inhibiting coagulation cascade.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
Initial adult dose: 5,000 units IV bolus, followed by continuous IV infusion at 1,000–2,000 units/hour; or 10,000–20,000 units subcutaneously every 12 hours. Dose adjusted based on aPTT.
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
Mean 1.5 hours (range 1-2 hours) after IV administration; increases with dose (e.g., 25,000 U IV: ~2.5 h). Clinical context: nonlinear pharmacokinetics; half-life prolonged in hepatic or renal impairment.
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Primarily renal (heparin is metabolized and excreted as uroheparin and other metabolites; up to 50% of administered dose appears in urine as unchanged heparin, but clearance is dose-dependent and nonlinear).
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category C
Category C
Anticoagulant
Anticoagulant